omation mbers - Society for Laboratory Automation and Screening

4:00 pm Wednesday, February 4 High Throughput Screening – Data Analysis and QC Room A2
Hanspeter Gubler
Novartis Institutes for BioMedical Research
WSJ-350.E15
Basel, CH-4002 Switzerland
hanspeter.gubler@pharma.novartis.com
65
Co-Author(s)
Michel Girod, Sigmar Dressler,
Rochdi Bouhelal, Daniela Gabriel,
Johannes Ottl, Kamal Azzaoui
HTS Data Analysis in the Real World: Practical Experience With HTS Data Quality Assurance
Systems and Recent Integration of the GeneData Screener Software
The application of comprehensive quality control and sophisticated data correction algorithms to High Throughput
Screening (HTS) data has a long standing history in the NIBR Lead Discovery Center (LDC). Fully automated inhouse
systems are sifting through HTS raw data to check quality and to detect and correct many systematic
errors. Some lacking aspects – most importantly interactive data visualization, comprehensive statistical analyses
and possibilities for easy cross-assay investigations – have led NIBR to enter into a system development
collaboration with GeneData in 2002.
The GeneData “Screener” software is tightly integrated to the LDC HTS data processing systems. Standardized
instrument raw data with necessary experimental context information are automatically entering the “Screener”
system in a near “real time” fashion. Data are thus readily available to the scientists for analysis and – if
necessary – correction of systematic patterns. Additional software modules are used for hit selection, including
results from other assays, either historical or direct counter screens. The combination of advanced assay
technology with the application of sophisticated quality control, error detection and data correction algorithms
(quality assurance) lead to improvements in HTS efficiency. We demonstrate this with a few case studies from our
HTS labs. In addition, we provide some further insight into the performance of the pattern correction algorithms by
applying them to simulated data of known intrinsic activity – and error structure.
4:30 pm Wednesday, February 4 High Throughput Screening – Data Analysis and QC Room A2
Maneessha Altekar
GlaxoSmithKline
709 Swedeland Road, Mail Stop UW2110
King of Prussia, Pennsylvania 19406-0939
maneesha.2.altekar@gsk.com
On-Line QC for High Throughput Screening
Co-Author(s)
Glenn Hofmann, Isabel Coma,
Jesus Herranz, Liz Clark,
Gavin Harper, Mark Lennon,
Frances Stewart
GlaxoSmithKline’s migration from the HTS laboratory to the HTS automation factory is expected to result in greater
throughput for screening. Thus there is a need to put data analysis systems in place to monitor the quality of the
screens in real time to ensure that any wastage of compounds, reagents and other materials is held to a minimum
if things go wrong during a run. The on-line QC process has been developed to perform plate level calculations
and determine the health of a plate or the screening run at any given time according to specified business rules.
Initially, plate failures or run stoppages due to business rules will be rare as screeners gain experience with using
the system and evaluate the sensitivity of the business rules being applied. The initial purpose of the system is
diagnosis rather than remedy, with the screeners being informed of problems as they occur. The ultimate goal
is to automate the system to provide feedback in to the screening process that will result in the robotic platform
pausing or stopping the run as appropriate.
PODIUM ABSTRACTS